Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Is there a role for a mucosal influenza vaccine in the elderly?
Autore:
Corrigan, EM; Clancy, RL;
Indirizzi:
Royal Newcastle Hosp, Fac Med & Hlth Sci, Discipline Pathol, Newcastle, NSW 2300, Australia Royal Newcastle Hosp Newcastle NSW Australia 2300 le, NSW 2300, Australia Royal Newcastle Hosp, Australian Inst Mucosal Immunol, Newcastle, NSW 2300, Australia Royal Newcastle Hosp Newcastle NSW Australia 2300 le, NSW 2300, Australia
Titolo Testata:
DRUGS & AGING
fascicolo: 3, volume: 15, anno: 1999,
pagine: 169 - 181
SICI:
1170-229X(199909)15:3<169:ITARFA>2.0.ZU;2-M
Fonte:
ISI
Lingua:
ENG
Soggetto:
A-VIRUS-VACCINES; CYTOTOXIC T-CELLS; IMMUNE-STIMULATING COMPLEXES; LOCAL ANTIBODY-RESPONSES; PLACEBO-CONTROLLED TRIAL; CHRONICALLY ILL ADULTS; TOXIN-B-SUBUNIT; INACTIVATED INFLUENZA; ORAL IMMUNIZATION; RESPIRATORY-TRACT;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
177
Recensione:
Indirizzi per estratti:
Indirizzo: Clancy, RL Royal Newcastle Hosp, Fac Med & Hlth Sci, Discipline Pathol, David Maddison Clin Sci Bldg, Newcastle, NSW 2300, Australia Royal Newcastle Hosp David Maddison Clin Sci Bldg Newcastle NSW Australia 2300
Citazione:
E.M. Corrigan e R.L. Clancy, "Is there a role for a mucosal influenza vaccine in the elderly?", DRUG AGING, 15(3), 1999, pp. 169-181

Abstract

Influenza infection is an acute respiratory disease with a high morbidity and significant mortality, particularly among the elderly and individuals with chronic diseases. The majority of countries now recommend annual influenza vaccination for all people aged 65 years or older, and for those with high risk conditions. Most commercially available influenza vaccines are administered systemically and while these are effective in children and young adults, efficacy levels in elderly individuals have been reported to be much lower. Mucosal vaccines may offer an improved vaccine strategy for protection of the elderly. As the influenza virus causes a respiratory infection,it is potentially more beneficial to administer a vaccine that will boost protection in the mucosal surfaces of the upper and lower respiratory tract. Mucosal influenza vaccines are aimed at stimulating protective immunity in the respiratory tract via oral or intranasal immunisation. This review examines our present knowledge of mucosal immunity and currentstrategies for mucosal vaccination. It also stresses that the use of serumantibody levels as a 'surrogate marker' for protection against influenza is potentially misleading; serum antibody, for example, may be a quite inappropriate marker to assess a mucosal vaccine. This marker does not reflect other immune responses to vaccination that are crucial for protection.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/07/20 alle ore 06:36:11